Provided by Tiger Trade Technology Pte. Ltd.

Immutep Limited

1.80
+0.02001.12%
Post-market: 1.77-0.0300-1.67%19:06 EST
Volume:59.79K
Turnover:107.86K
Market Cap:264.95M
PE:-6.51
High:1.86
Open:1.83
Low:1.78
Close:1.78
52wk High:2.71
52wk Low:1.32
Shares:147.19M
Float Shares:122.82M
Volume Ratio:0.45
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2767
EPS(LYR):-0.2767
ROE:-36.88%
ROA:-22.66%
PB:2.78
PE(LYR):-6.51

Loading ...

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire
·
Dec 02

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

GlobeNewswire
·
Nov 13

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

GlobeNewswire
·
Nov 03

Immutep Quarterly Activities Report Q1 FY26

GlobeNewswire
·
Oct 29

Immutep Limited Releases 2025 Corporate Governance Statement

TIPRANKS
·
Oct 24

Immutep Says its Mid-Stage Trial of Eftilagimod Alfa Meets Primary Endpoint of Tumor Hyalinization/Fibrosis

MT Newswires Live
·
Oct 20

Immutep announces Phase II study of eftilagimod alfa met primary endpoint

TIPRANKS
·
Oct 20

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

GlobeNewswire
·
Oct 20

Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

GlobeNewswire
·
Oct 20

Immutep announces update for TACTI-004 Phase III trial

TIPRANKS
·
Oct 09

Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti

GlobeNewswire
·
Sep 22

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

GlobeNewswire
·
Aug 05

Immutep Quarterly Activities Report Q4 FY25

GlobeNewswire
·
Jul 30

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

GlobeNewswire
·
Jul 28